{
    "organizations": [],
    "uuid": "0ceacd5e93a0be2396f9ec8e3847d866f75e930c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-selecta-biosciences-announces-fda/brief-selecta-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-lmb-100-and-svp-rapamycin-combination-therapy-idUSASB0BZFG",
    "ord_in_thread": 0,
    "title": "BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 13 PM / in 9 minutes BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy Reuters Staff 1 Min Read \nJan 2 (Reuters) - Selecta Biosciences Inc: \n* SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY \n* SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-01-02T15:12:00.000+02:00",
    "crawled": "2018-01-02T15:28:28.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "bioscience",
        "announces",
        "fda",
        "acceptance",
        "investigational",
        "new",
        "drug",
        "application",
        "combination",
        "therapy",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "selecta",
        "bioscience",
        "inc",
        "selecta",
        "bioscience",
        "announces",
        "fda",
        "acceptance",
        "investigational",
        "new",
        "drug",
        "application",
        "combination",
        "therapy",
        "selecta",
        "bioscience",
        "inc",
        "enrollment",
        "patient",
        "expected",
        "begin",
        "nci",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}